Pdt Partners, LLC Fate Therapeutics Inc Transaction History

Pdt Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.02 - $5.04 $280,404 - $699,622	138,814 New	138,814 $294,000
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $367,743 - $876,752	20,683 New	20,683 $513,000
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $932,018 - $1.25 Million	-19,482 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $1.15 Million - $1.87 Million	19,482 New	19,482 $1.16 Million
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $179,355 - $246,750	-2,667 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $192,450 - $313,105	2,667 New	2,667 $220,000
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $333,249 - $883,211	-8,749 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $266,057 - $354,334	8,749 New	8,749 $350,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $220M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.